Bibloc

Leaflet attached to the packaging: patient information

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Bibloc (BisoHEXAL 3.75 mg), 3.75 mg, coated tablets
Bisoprolol fumarate
Bibloc and BisoHEXAL 3.75 mg are different trade names for the same medicine.

You should read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same as yours.
• If you experience any side effects, including any not listed in this leaflet, you should tell your doctor or pharmacist. See section 4.

Table of contents of the leaflet:

• 1. What is Bibloc and what is it used for
• 2. Important information before taking Bibloc
• 3. How to take Bibloc
• 4. Possible side effects
• 5. How to store Bibloc
• 6. Contents of the packaging and other information

1. What is Bibloc and what is it used for

Bibloc belongs to a group of medicines called beta-blockers. They protect the heart from excessive activity.
Bibloc is used to treat:

• heart failure, which causes shortness of breath during exertion or fluid retention in the body. In such cases, Bibloc may be used as additional treatment for heart failure, which is being treated with other medicines.

2. Important information before taking Bibloc

When not to take Bibloc

• If you are allergic to bisoprolol fumarate or any of the other ingredients of this medicine (listed in section 6).
• If you have cardiogenic shock - a severe heart disorder with rapid, weak pulse, low blood pressure, cold, wet skin, weakness, and fainting.
• If you have ever had wheezing or severe bronchial asthma, as you may experience breathing difficulties.
• If you have a slow heart rate (less than 60 beats per minute). If in doubt, consult your doctor.
• If you have very low blood pressure.
• If you have severe circulatory disorders (which can cause tingling in the fingers and toes or their discoloration).
• If you have severe heart rhythm disorders.
• If you have suddenly developed heart failure or existing heart failure that is not controlled and requires hospital treatment.
• If you have a buildup of acids in the body, diagnosed as metabolic acidosis. Your doctor will provide information on this.
• If you have a tumor of the adrenal gland (so-called pheochromocytoma) that is not being treated.

If you have any doubts, you should consult your doctor.

Warnings and precautions

Before taking Bibloc, you should consult your doctor:

• if you have wheezing or difficulty breathing (bronchial asthma), you should also take medicines that dilate the airways. A higher dose of beta-2-mimetic may be necessary.
• if you have diabetes. Bibloc tablets may mask the symptoms of low blood sugar (such as rapid heart rate, palpitations, or excessive sweating).
• if you do not eat foods with a constant consistency.
• if you are being treated for allergies. Bibloc may increase sensitivity to allergens and worsen the severity of hypersensitivity reactions. Adrenaline treatment may not be effective and may require a higher dose.
• if you have a first-degree atrioventricular block (conduction disorders in the heart).
• if you have Prinzmetal's angina (chest pain caused by coronary artery spasm).
• if you have circulatory disorders in your hands and feet.
• if you are going to have surgery under anesthesia, you should inform your doctor, hospital staff, or dentist about the medicines you are taking.
• if you have or have had psoriasis (a recurring disease with skin peeling and dry skin rash).
• if you have a pheochromocytoma (adrenal gland tumor). Before prescribing Bibloc, your doctor will need to apply appropriate treatment.
• if you have thyroid function disorders. Bisoprolol tablets may mask the symptoms of hyperthyroidism.

There is currently no therapeutic experience with the use of Bibloc in heart failure in the following patients:

• with type 1 diabetes treated with insulin
• with severe kidney disease
• with severe liver disease
• with certain heart diseases
• who have had a heart attack in the last 3 months.

Treatment of heart failure with Bibloc requires systematic medical monitoring. This is absolutely necessary, especially at the beginning of treatment and after its completion.
Taking Bibloc should not be stopped suddenly without a compelling reason.
You should consult your doctor if any of the described warnings apply to you or have applied in the past.

Bibloc and other medicines

You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take. This includes medicines that are available without a prescription. Certain medicines should not be taken at the same time as Bibloc, and others may require changes, such as dose adjustments.
In any case, you should inform your doctor about taking or receiving the following medicines in addition to Bibloc:

• medicines used to control blood pressure or heart function disorders (such as amiodarone, amlodipine, clonidine, digitalis glycosides, diltiazem, disopyramide, felodipine, flecainide, lidocaine, methyldopa, moxonidine, phenytoin, propafenone, quinidine, rilmendine, verapamil);
• sedatives and medicines used to treat psychosis (a mental illness), such as barbiturates (also used to treat epilepsy), phenothiazines (also used to treat vomiting and nausea);
• medicines used to treat depression, such as tricyclic antidepressants, MAO-A inhibitors;
• medicines used for anesthesia during surgery (see also "Warnings and precautions");
• certain painkillers (such as acetylsalicylic acid, diclofenac, indomethacin, ibuprofen, naproxen);
• medicines used to treat bronchial asthma, nasal congestion, or certain eye diseases, such as glaucoma (increased pressure in the eyeball) or pupil dilation;
• certain medicines used to treat shock (such as adrenaline, dobutamine, noradrenaline);
• mefloquine (a medicine used to treat malaria);
• rifampicin (an antibiotic);
• ergotamine derivatives (used to treat migraines). All these medicines and Bibloc may affect blood pressure and/or heart function.
• insulin or other anti-diabetic medicines. There is a possibility of enhanced glucose-lowering effect and masking of low blood sugar symptoms.

Bibloc and alcohol

Alcohol may enhance the dizziness and fainting caused by Bibloc. In such cases, you should avoid drinking alcohol.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor before taking this medicine. Bibloc may have a harmful effect on the course of pregnancy and/or the fetus. The risk of premature birth, miscarriage, low blood sugar in the child, and slowed heart rate increases. The medicine may also affect the development of the child. Therefore, Bibloc should not be taken during pregnancy.
It is not known whether bisoprolol passes into breast milk, so it is not recommended to take Bibloc while breastfeeding.

Driving and operating machines

The medicine may cause fatigue, drowsiness, or dizziness. If you experience these symptoms, you should not drive or operate machines. You should be aware that such symptoms may occur, especially at the beginning of treatment, when changing the medicine, or when consuming alcohol.

Bibloc contains lactose and sodium

If you have been diagnosed with intolerance to some sugars, you should contact your doctor before taking the medicine.
This medicine contains less than 1 mmol (23 mg) of sodium per coated tablet, which means that the medicine is considered "sodium-free".

3. How to take Bibloc

This medicine should always be taken as directed by your doctor or pharmacist. If you have any doubts, you should consult your doctor or pharmacist.
Your doctor will inform you how many tablets to take. The medicine should be taken in the morning, before, during, or after breakfast. The tablet(s) should be swallowed with a small amount of water. The tablets should not be chewed or crushed.
The usual dose is:

Heart failure (reduced heart contractility)

Before starting treatment with Bibloc, you are usually already taking an ACE inhibitor, diuretic, or digitalis glycoside (a heart medicine and antihypertensive).
The dose of Bibloc will be gradually increased until the optimal dose for you is reached:
1.25 mg once a day for 1 week. If this dose is well tolerated, it can be increased to:
2.5 mg once a day for the next week. If this dose is well tolerated, it can be increased to:
3.75 mg once a day for the next week. If this dose is well tolerated, it can be increased to:
5 mg once a day for 4 consecutive weeks. If this dose is well tolerated, it can be increased to:
7.5 mg once a day for 4 consecutive weeks. If this dose is well tolerated, it can be increased to:
10 mg once a day (maintenance dose).
The maximum dose is 10 mg once a day.
Your doctor will determine the optimal dose for you based on, among other things, side effects.
After taking the first dose of 1.25 mg, your doctor will check your blood pressure, heart rate, and heart function.
Liver or kidney function disorders
Your doctor will increase the dose of Bibloc with caution.
Elderly
Dose adjustment is usually not necessary.
If you feel that the effect of Bibloc is too strong or too weak, you should inform your doctor or pharmacist.
The tablet should be placed on a hard, flat surface, with the notch facing up.
Press your thumb on the center of the tablet. The tablet will break into 3 parts.

Duration of treatment

Bibloc is usually taken long-term.

Use in children and adolescents

Due to the lack of studies on the effect of Bibloc in children and adolescents, its use is not recommended in this age group.

Taking a higher dose of Bibloc than recommended

In case of unintentional ingestion of a higher dose than recommended, you should immediately contact
your doctor or pharmacist. You should take the remaining tablets or this leaflet with you, so that the medical staff knows what medicine has been taken. Symptoms of overdose may include dizziness, fainting, fatigue, shortness of breath and/or wheezing. Slow heart rate, low blood pressure, inadequate heart contractions, and low blood sugar (which can cause hunger, excessive sweating, and palpitations) may also occur.

Missing a dose of Bibloc

You should not take a double dose to make up for a missed dose. You should take the usual dose as soon as you remember, and the next day return to the normal dosing schedule.

Stopping treatment with Bibloc

Treatment with Bibloc should not be stopped suddenly. If treatment is stopped suddenly, the disease may worsen. The dose of Bibloc should be gradually reduced over several weeks, as directed by your doctor.
If you have any further doubts about taking this medicine, you should consult your doctor or pharmacist.

4. Possible side effects

Like all medicines, Bibloc can cause side effects, although not everybody gets them.
If a side effect is serious, occurs suddenly, or worsens rapidly, you should contact your doctor immediately to prevent severe reactions.
The most serious side effects are related to heart function:

• slow heart rate (may occur more frequently than in 1 in 10 people)
• worsening of existing heart failure (may occur less frequently than in 1 in 10 people)
• slow or irregular heart rate (may occur less frequently than in 1 in 100 people)

If you experience dizziness, weakness, or difficulty breathing, you should contact your doctor as soon as possible.
If you experience severe hypersensitivity reactions, which can include swelling of the face, neck, tongue, lips, or throat, or difficulty breathing, you should contact your doctor immediately.
The following side effects are listed below by frequency of occurrence:
Common (may occur less frequently than in 1 in 10 people):

• fatigue, exhaustion
• dizziness
• headache
• feeling of cold or numbness in the fingers and toes, ears, and nose; more frequent occurrence of cramping leg pain while walking
• very low blood pressure (hypotension), especially in patients with heart failure
• nausea, vomiting
• diarrhea
• constipation

Uncommon (may occur less frequently than in 1 in 100 people):

• decrease in blood pressure when standing up, which can cause dizziness, fainting, or lightheadedness
• sleep disorders
• depression
• irregular heart rate
• breathing difficulties in patients with bronchial asthma or a history of breathing disorders
• muscle weakness and cramps

Rare (may occur less frequently than in 1 in 1,000 people):

• nightmares
• hallucinations
• fainting
• hearing impairment
• nasal congestion, causing a runny nose with irritation
• skin allergic reactions (such as itching, sudden redness of the skin, rash)
• dryness of the conjunctiva due to reduced tear secretion (which can be very troublesome in patients wearing contact lenses)
• liver inflammation, causing abdominal pain, loss of appetite, and sometimes jaundice with yellowing of the eyes and skin, as well as dark urine
• reduced sexual potency (impotence)
• increased blood lipid levels (triglycerides) and increased liver enzyme activity

Very rare (may occur less frequently than in 1 in 10,000 people):

• exacerbation of psoriasis symptoms or occurrence of a similar, dry, flaky rash, as well as hair loss
• itching or redness of the eyes (conjunctivitis)

Reporting side effects

If you experience any side effects, including any not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Bibloc

• The medicine should be stored out of sight and reach of children.
• Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
• Translation of some information on the immediate packaging: Ch.-B./verwendbar bis siehe Prägung- batch number/expiry date - see imprint.
• There are no special precautions for storage.
• Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Bibloc contains

• The active substance is bisoprolol fumarate. Each coated tablet contains 3.75 mg of bisoprolol fumarate.
• The other ingredients are: calcium hydrogen phosphate, microcrystalline cellulose, maize starch, cross-linked carboxymethylcellulose sodium, colloidal anhydrous silica, magnesium stearate. Coating: lactose monohydrate, hypromellose, titanium dioxide (E 171), macrogol 4000, yellow iron oxide (E 172).

What Bibloc looks like and what the packaging contains

Yellow-white, round, coated tablets with a notch, marked "BIS 3.75" on one side.
The tablets can be divided into three equal doses.
The coated tablets are packaged in blisters of OPA/Aluminum/PVC/Aluminum foil in a cardboard box containing 25, 30, 50, 60, 90, or 100 tablets.
For more detailed information, you should contact the marketing authorization holder or parallel importer.

Marketing authorization holder in Germany, the country of export:

Hexal AG
Industriestraße 25
83607 Holzkirchen
Germany

Manufacturer:

Salutas Pharma GmbH
Otto-von-Guericke-Allee 1
39179 Barleben
Germany
Lek S.A.
ul. Podlipie 16
95-010 Stryków
Poland
ROWA Pharmaceuticals Limited
Newtown, Bantry, Co. Cork
Ireland
Lek Pharmaceuticals d.d.
Verovskova ulica 57
1526 Ljubljana
Slovenia
Lek S.A
ul. Domaniewska 50 C
02-672 Warsaw
Poland

Parallel importer:

InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw

Repackaged by:

Pharma Innovations Sp. z o.o.
ul. Jagiellońska 76
03-301 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Authorization number in Germany, the country of export:71880.00.00
Parallel import authorization number:193/19

Date of leaflet approval: 15.04.2024

[Information about the trademark]